Gemtuzumab ozogamicin in combination with attenuated doses of standard induction chemotherapy can successfully induce complete remission without increasing toxicity in patients with acute myeloid leukemia aged 55 or older

European Journal of Haematology

Volumn 79, Issue 5, 2007, Pages 398-404

  Eom, Ki Seong ^a   Kim, Hee Je ^a   Min, Woo Sung ^a   Lee, Seok ^a   Min, Chang Ki ^a   Cho, Byung Sik ^a   Kim, Sung Yong ^a   Kim, Yoo Jin ^a   Lee, Dong Gun ^a   Choi, Su Mi ^a   Cho, Seok Goo ^a   Kim, Dong Wook ^a   Lee, Jong Wook ^a   Shin, Wan Shik ^a   Kim, Chun Choo ^a  

^a The Catholic University of Korea   (South Korea)

Author keywords

Acute myeloid leukemia; Elderly; Gemtuzumab ozogamicin; Induction chemotherapy

Indexed keywords

DEXAMETHASONE; ENOCITABINE; GEMTUZUMAB OZOGAMICIN; IDARUBICIN;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; ASTHENIA; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; MALE; MUCOSA INFLAMMATION; NAUSEA; NEUTROPENIA; NEUTROPHIL COUNT; PRIORITY JOURNAL; THROMBOCYTE COUNT; THROMBOCYTOPENIA; WEIGHT GAIN;

AGED; AMINOGLYCOSIDES; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DRUG ADMINISTRATION SCHEDULE; FEASIBILITY STUDIES; FEMALE; HUMANS; LEUKEMIA, MYELOCYTIC, ACUTE; MALE; MIDDLE AGED; REMISSION INDUCTION; TREATMENT OUTCOME;

EID: 35048837063     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/j.1600-0609.2007.00946.x     Document Type: Article

References (25)

1. Johnson PR, Hunt LP, Yin JA. Prognostic factors in elderly patients with acute myeloid leukemia: development of a model to predict survival. Br J Haematol 1993 85 : 300 6.
2. Preisler H, Davis RB, Kirshner J, et al. Comparison of the three remission induction regimens and two postinduction strategies for the treatment of acute nonlymphocytic leukemia: a Cancer and Leukemia Group B study. Blood 1987 69 : 1441 9.
3. Mayer RJ, Davis RB, Schiffer CA, et al. Intensive postremssion chemotherapy in adults with acute myeloid leukemia. New Engl J Med 1994 331 : 896 903.
4. Löwenberg B, Suciu S, Archimbaud E, et al. Mitoxantrone vs daunorubicin in induction -consolidation chemotherapy: the value of low-dose cytarabine for maintenance of remission, and an assessment of prognostic factors in acute myeloid leukemia in the elderly. J Clin Oncol 1998 16 : 872 81.
5. Taylor PR, Reid MM, Stark AN, et al. De-novo acute myeloid leukemia in patients over 55 years old: a population based study of incidence, treatment and outcome. Leukemia 1995 9 : 231 7.
6. Estey EH, Thall PF, Giles FJ, et al. Gemtuzumab ozogamicin with or without interleukin 11 in patients 65 years of age or older with untreated acute myeloid leukemia and high-risk myelodysplastic syndrome: comparison with idarubicin plus continuous-infusion, high-dose cytosine arabinoside. Blood 2002 99 : 4343 9.
7. Amadori S, Suciu S, Willemze R, et al. Sequential administration of gemtuzumab ozogamicin and conventional chemotherapy as first line therapy in elderly patients with acute myeloid leukemia: a phase II study (AML-15) of EORTC and GIMEMA leukemia groups. Haematologica 2004 89 : 950 6.
8. Kell WJ, Burnett AK, Chopra R, et al. A feasibility study of simultaneous administration of gemtuzumab ozogamicin with intensive chemotherapy in induction and consolidation in younger patients with acute myeloid leukemia. Blood 2003 102 : 4277 83.
9. Alvarado Y, Tsimberidou A, Kantarjian H, et al. Pilot study of Mylotarg, idarubicin and cytarabine combination regimen in patients with primary resistant or relapsed acute myeloid leukemia. Cancer Chemother Pharmacol 2003 51 : 87 90.
10. Tsimberidou A, Cortes J, Thomas D, et al. Gemtuzumab ozogamicin, fludarabine, cytarabine and cyclosporine combination regimen in patients with CD33+ primary resistant or relapsed acute myeloid leukemia. Leuk Res 2003 27 : 893 7.
11. Cheson BD, Bennett JM, Kopecky KJ, et al. Revised recommendations of the International Working Group for Diagnosis. Standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia. J Clin Oncol 2003 21 : 4642 9.
12. Shaffer LG, Tommerup N. ISCN 2005: An International System for Human Cytogenetic Nomenclature (Cytogenetic & Genome Research). Basel : S. Karger AG, 2005.
13. Appelbaum F, Rowe J, Radich J, et al. Acute myeloid leukemia. Hematology (Am Soc Hematol Educ Program) 2001 : 62 86.
14. Büchner T, Berdel WE, Wörmann B, et al. Treatment of older patients with AML. Crit Rev Oncol Hematol 2005 56 : 247 59.
15. Rowe JM, Neuberg D, Friedenberg W, et al. A phase 3 study of three induction regimens and of priming with GM-CSF in older adults with acute myeloid leukemia: a trial by the Eastern Cooperative Oncology Group. Blood 2004 15 : 479 85.
16. Goldstone AH, Burnett AK, Wheatley K, et al. Attempts to improve treatment outcomes in acute myeloid leukemia (AML) in older patients: the results of the United Kingdom Medical Research Council AML11 trial. Blood 2001 98 : 1302 11.
17. Anderson J, Kopecky K, Willman C, et al. Outcome after induction chemotherapy for older patients with acute myeloid leukemia is not improved with mitoxantrone and etoposide compared to cytarabine and daunorubicin: a Southwest Oncology Group study. Blood 2002 100 : 3869 76.
18. van der Holt B, Löwenberg B, Burnett AK, et al. The value of the MDR1 reversal agent PSC-833 in addition to daunorubicin and cytarabine in the treatment of elderly patients with previously untreated acute myeloid leukemia (AML), in relation to MDR1 status at diagnosis. Blood 2005 15 : 2646 54.
19. Leith CP, Kopecky KJ, Godwin J, et al. Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study. Blood 1997 89 : 3323 9.
20. Arlin Z, Case D, Moore J, et al. Randomized multicenter trial of cytosine arabinoside with mitoxantrone or daunorubicin in previously untreated adult patients with acute nonlymphocytic leukemia (ANLL). Leukemia 1990 4 : 177 83.
21. Weick J, Kopecky K, Appelbaum F, et al. A randomized investigation of high-dose versus standard-dose cytosine arabinoside with daunorubicin in patients with previously untreated acute myeloid leukemia: a Southwest Oncology Group Study. Blood 1996 88 : 2841 51.
22. Hiddemann W, Kern W, Schoch C, et al. Management of acute myeloid leukemia in elderly patients. J Clin Oncol 1999 17 : 3569 76.
23. Baker WJ, Royer GL Jr., Weiss RB. Cytarabine and neurologic toxicity. J Clin Oncol 1991 9 : 679 93.
24. Park HS, Kim DW, Kim CC, et al. Induction chemotherapy with idarubicin plus N4-Behenoyl-1-β-d-Arabinofuranosylcytosine in acute myelogenous leukemia: a newly designed induction regimen: a prospective, Cooperative Multicenter Study. Semin Hematol 1996 4 (Suppl. 3 24 29.
25. Giles F, Estey E, O'Brien S. Gemtuzumab ozogamicin in the treatment of acute myeloid leukemia. Cancer 2003 98 : 2095 104.